Objectives The active form of vitamin D, 1a, 2 D 3 ), is reported to have protective effects for multiple sclerosis (MS), but the precise mechanisms of this effect on MS remain unclear. We hypothesized that 1a,25-(OH) 2 D 3 has protective effects on the blood-brain barrier (BBB) in MS. Methods The expression of vitamin D receptor in a human brain microvascular endothelial cell line (HBMEC) was examined. The effects of 1a,25-(OH) 2 D 3 on HBMEC after stimulation with tumor necrosis factor-a were observed. In addition, we assessed the effects of sera from MS patients, including those in the acute and stable phase of relapse-remitting MS or secondary progressive MS, on the BBB property in the presence or absence of 1a,25-(OH) 2 D 3 . Results HBMEC were found to express the vitamin D receptor at both the mRNA and protein level. Pretreatment of HBMEC with 1a,25-(OH) 2 D 3 attenuated the decrease of zonula occludens-1 and claudin-5, and the increase of intercellular adhesion molecule-1 (ICAM-1) induced by tumor necrosis factor-a. In addition, nuclear factor kappa B activation mediated by tumor necrosis factor-a was decreased after incubation with the activated vitamin D. Furthermore, incubation with 1a,25-(OH) 2 D 3 attenuated the increase of vascular cell adhesion molecule-1 and anti-phospho-nuclear factor kappa B in HBMEC after exposure to sera from patients with relapse-remitting MS and secondary progressive MS, and restored the decrease of zonula occludens-1 and claudin-5 in HBMEC after incubation with sera from the acute phase of relapse-remitting MS patients. Conclusions Treatment with 1a,25-(OH) 2 D 3 prevents BBB disruption caused by both relapse-remitting MS and secondary progressive MS sera through upregulation of tight junction proteins and downregulation of cell adhesion molecules in HBMEC, suggesting that 1a,25-(OH) 2 D 3 might have the direct protective effects on the fragile BBB in MS patients.